137 related articles for article (PubMed ID: 31409909)
1. De novo regulation of RD3 synthesis in residual neuroblastoma cells after intensive multi-modal clinical therapy harmonizes disease evolution.
Somasundaram DB; Subramanian K; Aravindan S; Yu Z; Natarajan M; Herman T; Aravindan N
Sci Rep; 2019 Aug; 9(1):11766. PubMed ID: 31409909
[TBL] [Abstract][Full Text] [Related]
2. RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes.
Khan FH; Pandian V; Ramraj SK; Aravindan S; Natarajan M; Azadi S; Herman TS; Aravindan N
Oncotarget; 2015 Nov; 6(34):36522-34. PubMed ID: 26375249
[TBL] [Abstract][Full Text] [Related]
3. Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes.
Khan FH; Pandian V; Ramraj S; Natarajan M; Aravindan S; Herman TS; Aravindan N
BMC Cancer; 2015 Jul; 15():514. PubMed ID: 26159519
[TBL] [Abstract][Full Text] [Related]
4. Retinal Degeneration Protein 3 (RD3) in normal human tissues: Novel insights.
Aravindan S; Somasundaram DB; Kam KL; Subramanian K; Yu Z; Herman TS; Fung KM; Aravindan N
Sci Rep; 2017 Oct; 7(1):13154. PubMed ID: 29030614
[TBL] [Abstract][Full Text] [Related]
5. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.
Pandian V; Ramraj S; Khan FH; Azim T; Aravindan N
Stem Cell Res Ther; 2015 Feb; 6(1):2. PubMed ID: 25888913
[TBL] [Abstract][Full Text] [Related]
6. Extracellular vesicles in neuroblastoma: role in progression, resistance to therapy and diagnostics.
Dhamdhere MR; Spiegelman VS
Front Immunol; 2024; 15():1385875. PubMed ID: 38660306
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of combination therapy using adeno-associated virus--interferon beta and trichostatin A in vitro and in a murine model of neuroblastoma.
Hamner JB; Sims TL; Cutshaw A; Dickson PV; Rosati S; McGee M; Ng CY; Davidoff AM
J Pediatr Surg; 2008 Jan; 43(1):177-82; discussion 182-3. PubMed ID: 18206478
[TBL] [Abstract][Full Text] [Related]
8. Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells.
Khan FH; Pandian V; Ramraj S; Aravindan S; Herman TS; Aravindan N
BMC Genomics; 2015 Jul; 16(1):501. PubMed ID: 26148557
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a neuroblastoma mouse model by subcutaneous xenograft transplantation and its use to study metastatic neuroblastoma.
Gao Q; Chen CF; Dong Q; Hou L; Chen X; Zhi YL; Li X; Lu HT; Zhang HY
Genet Mol Res; 2015 Dec; 14(4):16297-307. PubMed ID: 26662423
[TBL] [Abstract][Full Text] [Related]
10. Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease.
Ramraj SK; Aravindan S; Somasundaram DB; Herman TS; Natarajan M; Aravindan N
Oncotarget; 2016 Apr; 7(14):18605-19. PubMed ID: 26921195
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD44 is associated with a metastatic pattern of human neuroblastoma cells in a SCID mouse xenograft model.
Valentiner U; Valentiner FU; Schumacher U
Tumour Biol; 2008; 29(3):152-60. PubMed ID: 18612220
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Keshelava N; Seeger RC; Groshen S; Reynolds CP
Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
14. LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.
Dorneburg C; Fischer M; Barth TFE; Mueller-Klieser W; Hero B; Gecht J; Carter DR; de Preter K; Mayer B; Christner L; Speleman F; Marshall GM; Debatin KM; Beltinger C
Clin Cancer Res; 2018 Nov; 24(22):5772-5783. PubMed ID: 29925504
[No Abstract] [Full Text] [Related]
15. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
16. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model.
Kotchetkov R; Cinatl J; Blaheta R; Vogel JU; Karaskova J; Squire J; Hernáiz Driever P; Klingebiel T; Cinatl J
Int J Cancer; 2003 Mar; 104(1):36-43. PubMed ID: 12532417
[TBL] [Abstract][Full Text] [Related]
17. Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma.
Gebauer S; Yu AL; Omura-Minamisawa M; Batova A; Diccianni MB
Genes Chromosomes Cancer; 2004 Dec; 41(4):297-308. PubMed ID: 15390183
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of surveillance radiographic imaging in detecting progressive disease in children with advanced stage neuroblastoma.
Bruggers CS; Bolinger C
J Pediatr Hematol Oncol; 1998; 20(2):104-7. PubMed ID: 9544158
[TBL] [Abstract][Full Text] [Related]
19. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
Anderson CP; Reynolds CP
Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
[TBL] [Abstract][Full Text] [Related]
20. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth.
Streck CJ; Zhang Y; Zhou J; Ng C; Nathwani AC; Davidoff AM
J Pediatr Surg; 2005 Jan; 40(1):236-43. PubMed ID: 15868591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
